LRG1预测了预后,并且与甲状腺癌的免疫透有关:生物信息学研究
Zherui Fu1, Yi Lai1, Qianfei Wang1
1Department of Emergency, The First People's Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, Zhejiang, China.
Endocrine connections
|November 22, 2023
概括
富含白的α-2-糖蛋白1 (LRG1) 在甲状腺癌中表达高,使其与正常组织区别开来. 高LRG1表达与更好的生存和免疫细胞透相关,表明其作为预后生物标志物的潜力.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 免疫学 免疫学 免疫学
背景情况:
- 甲状腺癌中富含白的α-2-糖蛋白1 (LRG1) 的诊断和预后意义尚未得到充分确立.
- 使用癌症基因组图谱 (TCGA) 数据库进行生物信息学分析,以调查LRG1的作用.
研究的目的:
- 评估LRG1在甲状腺癌中的诊断和预后价值.
- 探索LRG1表达与临床病理特征,生存结果和甲状腺癌免疫透之间的关联.
主要方法:
- 利用了来自512名甲状腺癌患者和59名正常人的TCGA数据.
- 采用了克鲁斯卡尔-瓦利斯测试,物流分析,考克斯回归,卡普兰-梅尔分析和ssGSEA.
- 检查了LRG1表达,其与临床病理学特征的相关性,存活率和免疫细胞透.
主要成果:
- 在甲状腺癌中,LRG1显著上调,使瘤与正常组织区分开来 (AUC=0.875).
- 高LRG1表达与更好的整体存活率 (HR=0.30) 有关,并与病态N阶段 (OR=2.411) 相相关.
- LRG1表达与T辅助1细胞,树突细胞和巨细胞正相关.
结论:
- LRG1作为甲状腺癌的潜在诊断生物标志物.
- LRG1可能是一个有价值的预后生物标志物,用于预测患者的结果.
- LRG1可能是与甲状腺癌免疫透相关的免疫治疗的治疗标.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
03:18Non-LTR Retrotransposons
11.5K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.5K